It has been found that acrylamide is neurotoxic, producing central-peripheral axonopathies. The animal species in which this effect was demonstrated include rats, mice, cats, dogs, baboons, and monkeys. In addition, there are at least 48 published cases of the occupational toxicity and 5 cases of the nonoccupational toxicity of acrylamide to humans, many of whom manifested a measurable degree of neurotoxicity (central-peripheral axonopathy). In humans, the predominant signs of neurotoxicity are related to peripheral nerve involvement and, to a lesser extent, central nervous system involvement. A variety of other signs and symptoms also are generally reported, the most common ones occurring in the skin, hands, and feet. The onset of effects may be reversible, although this is not always the case. Based on laboratory data, EPA has concluded that acrylamide is a potent neurotoxicant at very low levels. This conclusion has been substantiated by a 1-year (oral administration) study in cats indicating a no-effect level of 0.3-1.0 mg/kg/day. EPA does not plan to require the health effects testing recommended by the Interagency Testing Committee. Instead, EPA plans to evaluate acrylamide for possible regulatory controls.

Cover title: Assessment of testing needs : acrylamide : support document for decision not to require testing for health effects, Toxic Substances Control Act, Section 4. "EPA-560/11-80-016." "June 1980."